INCB123667 Plus Bevacizumab Shows Antitumor Activity in Recurrent Epithelial Ovarian Cancer
INCB123667 plus bevacizumab (Avastin) induced objective responses in heavily pretreated patients with platinum-resistant or platinum-refractory ovarian cancer and cyclin E1 overexpression, according to preliminary data...
